Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
Globe Newswire•13/10/2026•16:30 ET
0
Key Highlights
- ➤Generate receives $30M upfront for two initial programs.
- ➤Generate eligible for nearly $1.2B in total milestones.
- ➤Generate receives up to $35M in early preclinical milestones.
- ➤Zealand Pharma assumes clinical development, regulatory, and commercialization responsibilities.
- ➤Collaboration targets multispecific protein therapeutics for obesity and metabolic diseases.
Expert Statements
Utpal Singh, Chief Scientific Officer of Zealand Pharma
“We are thrilled to collaborate with Generate, a leader in AI and structure-enabled drug generation. This collaboration expands our toolbox to include proteins, complementing our existing small-molecule and peptide capabilities and opening new approaches for polypharmacology for innovative therapeutics.”
Utpal Singh, Chief Scientific Officer of Zealand Pharma
“This collaboration reflects our strategy of expanding our platform and integrating our metabolic expertise in Copenhagen with the multi-modality expertise in Cambridge to develop next-generation therapeutics for metabolic health.”
Mike Nally, Chief Executive Officer of Generate Biomedicines
“We are excited to bring together Zealand Pharma’s deep expertise in peptide therapeutics and metabolic disease with Generate’s cutting-edge computational platform and experimental capabilities to address the continued unmet medical needs of patients with cardiometabolic disease.”
Mike Nally, Chief Executive Officer of Generate Biomedicines
“Together, our teams will first define what a great medicine for patients looks like for each of the two initial programs, and then leverage The Generate Platform to design multispecific candidates that meet or exceed that profile.”
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions
Generate will receive $30M upfront, up to $35M in early preclinical milestones, and a total of up to nearly $1.2B in milestones, plus tiered royalties for two initial programs, with an option to add a third
Get started
Create a free account to read the full story.